Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients


Arslan U. Y. , Turker I., Aksoy S., Oksuzoglu B., Helvaci K., Ozdemir N. Y. , ...More

JOURNAL OF BUON, vol.18, no.3, pp.585-593, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 3
  • Publication Date: 2013
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.585-593

Abstract

Purpose: The duration of anti-HER2 blockage therapy in metastatic breast cancer patients is still unclear. We aimed to evaluate the effect of the anti-HER2 blockage therapy duration and other factors on survival in HER2 positive metastatic breast carcinoma (MBC) patients.